Why the study?
Traditional imaging depends on luminal stenosis and underestimates non-stenotic high-risk plaque, leaving the identification of vulnerable atherosclerotic plaques limited.
Design
Review
Authors
Loading...
Should not yet change plaque imaging practice; leaves open targeted nanomedicine validation in prospective trials.
Targeted nanomedicines hold significant potential for improving the imaging and risk stratification of vulnerable atherosclerotic plaques compared to traditional luminal diameter quantification.
Li et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: